The munKNEE Psychedelic Drug Stocks Index tracks the six (6) largest psychedelic stocks, by market capitalization, that research the treatment of mental illnesses based on the use of one or more of ten (10) different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them). Below are their performances this week and YTD:

1. GH Research (GHRS): down 1.6% this week; up 0.9% YTD
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
2. Cybin (CYBN): down 2.4% this week; up 37.9% YTD
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
3. Mind Medicine (MNMD): down 2.8% this week; up 57.8% YTD 
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
4. Atai (ATAI): down 5.8% this week; down 30.6% YTD
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
5. Compass Pathways (CMPS): down 8.3% this week; up 37.0% YTD
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
6. Seelos (SEEL): down 12.9% this week; up 24.6% YTD
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.

In total, the Index went up 1.2% this week and is now up 16.1% YTD.

Six (6) other psychedelic companies are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, substance abuse withdrawal, and depression. All are highly speculative investments and penny stocks with tiny market capitalization. They are as follows, in alphabetical order:

1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF);
2. Delic Corp. (CSE: DELC|OTCQB: DELCF);
3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF);
4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF);
5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF);
6.  Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)

The above psychedelic-assisted therapy clinic stocks went up 0.2%, on average, this week and are now up 23.5% YTD.

More By This Author:

Largest Cannabis LPs: Up 5% This Week, 16% YTD
An Easy Way To Invest In Bitcoin
The "Multi-Bagger" Portfolio Update: January 20th, 2023